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Abstract We have partially sequenced rabbit skeletal muscle 
T-sarcoglycan an integral component of the dystrophin-glyco- 
protein complex. Specific antibodies were produced against a 
7-sarcoglycan peptide and used to examine the expression of 
T-sarcoglycan in skeletal muscle of patients with severe childhood 
autosomal muscular dystrophy linked to chromosome 13q12 
(SCARMD). We show by immunofluorescence and Western 
blotting that in skeletal muscle from these patients T-sarcoglycan 
is completely absent and c~- and ~-sarcoglycan are greatly 
reduced in abundance, whereas other components of the DGC are 
preserved. In addition, we show that in normal muscle ~-, ~-, and 
T-sarcoglycan constitute a tightly associated sarcolemma com- 
plex which can not be disrupted by SDS treatment. 
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I. Introduction 
Dystrophin, the product of the Duchenne muscular dystro- 
phy gene [1], binds F-actin through its N-terminal domain [2] 
and is tightly associated with a large sarcolemma protein com- 
plex through its cysteine-rich and C-terminal domains [3-11]. 
This complex consists of c~-dystroglycan,  156 kDa extracel- 
lular laminin-binding glycoprotein [12]; syntrophin, a 59 kDa 
intracellular protein triplet [13]; adhalin (or ~x-sarcoglycan), a 
50 kDa transmembrane glycoprotein [14]; ~-sarcoglycan, a 43 
kDa transmembrane glycoprotein [15,16]; l~-dystroglycan, a 
43 kDa transmembrane glycoprotein [12]; 35 DAG or 7-sar- 
coglycan [17], a 35 kDa transmembrane glycoprotein; and a 
25 kDa transmembrane protein. One function of the dystro- 
phin-glycoprotein complex (DGC) in skeletal muscle is to act 
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as a molecular link between the extracellular matrix, via lami- 
nin 2, and the actin cytoskeleton, via dystrophin [18,19]. 
The DGC may play an important role in maintaining mus- 
cle fiber stability. Defects in DGC components lead to muscle 
fiber necrosis, which is the major pathologic event in progres- 
sive muscular dystrophy. The most severe muscular dystrophy 
is Duchenne muscular dystrophy (DMD) in which mutations 
in the dystrophin gene cause the complete absence of dystro- 
phin and a drastic reduction of the dystrophin-associated pro- 
teins [20]. Several cases of severe childhood autosomal reces- 
sive muscular dystrophy (SCARMD) which closely resembles 
DMD have been reported [21]. c~-Sarcoglycan immunostain- 
ing at the sarcolemma of these SCARMD patients is drama- 
tically reduced compared to control [22]. A less severe reduc- 
tion of the 35 kDa component of the DGC is also observed 
whereas the other components of the DGC are preserved [22]. 
These criteria have allowed distinction between SCARMD 
and DMD. SCARMD was first linked to the pericentromeric 
region of chromosome 13q12 in several North African fam- 
ilies [23-25] and excluded from the 13q locus in non-North 
African families [26,27]. Therefore, mutations in at least two 
independent genes may cause SCARMD. The e~-sarcoglycan 
gene has been localized to chromosome 17q21 and mutations 
in this gene have been demonstrated to be responsible for 
SCARMD [28-30], also referred to limb-girdle muscular dys- 
trophy type 2D (LGMD2D) [31]. Therefore, SCARMD 
linked to chromosome 13q12 has been suggested as caused 
by a defect in the 35 DAG gene although this protein has 
never been shown to be completely absent in SCARMD pa- 
tients. Recently, mutations in the 13-sarcoglycan gene, located 
on chromosome 4q12, have been shown to be responsible for 
LGMD2E [15,16]. Immunofluorescence analysis of skeletal 
muscle from LGMD2E patients howed a great reduction or 
absence of 13-sarcogtycan concomitant with a reduction of ~x- 
and 7-sarcoglycan. SCARMD linked to chromosome 13q12 
has been renamed LGMD2C [30] and recently Noguchi et 
al. [17] reported the identification of the 35 DAG gene on 
chromosome 13q12. Furthermore, they identified mutations 
in the y-sarcoglycan gene in LGMD2C. 
In this study, we have isolated and cleaved the 35 kDa 
component of the DGC into different peptides which have 
been sequenced after HPLC purification. Eight different pep- 
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tide sequences representing one-third of the apparent molecu- 
lar mass of y-sarcoglycan were obtained. Specific polyclonal 
antibodies were raised against one of these peptides and used 
to examine the tissue distr ibution of y-sarcoglycan. The status 
of y-sarcoglycan was also determined by immunofluorescence 
and Western blott ing of skeletal muscle from patients with 
LGMD2C.  We observed a specific absence of y-sarcoglycan 
together with a drastic, but not complete reduction of c~- and 
[3-sarcoglycan. In addition, we show that in normal muscle e~-, 
[~-, and y-sarcoglycan constitute a tightly associated sarcolem- 
ma complex which cannot  be disrupted by SDS treatment. 
2. Materials and methods 
Tryptic peptides were prepared for acquisition of internal sequence 
information by SDS-PAGE of purified DGC [3] through 10% poly- 
acrylamide gels, electrotransffered to PVDF membranes. The protein 
band corresponding to the 35 kDa protein was excised. The immobi- 
lized protein was then digested with trypsin as previously described 
[32]. Peptides were purified by reverse phase HPLC using Applied 
Biosystems model 130A HPLC system equipped with 2.1 ×100 mm 
RP-300 column. The purified tryptic peptides were sequenced by 
Automated Edman degradation using an Applied Biosystems model 
470A Sequencer equipped with an on-line model 120A phenylthiohy- 
dantoin derivative analyzer using the manufacturer's standard pro- 
gramming and chemicals. 
Peptides corresponding to the rabbit skeletal muscle y-sarcoglycan 
sequences were chemically synthesized with an additional cysteine at 
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the N-terminus. These synthetic peptides were conjugated through the 
N-terminal cysteine to keyhole limpet hemocyanin (Pierce Chemical 
Co) using m-maleimidobenzoic acid/N-hydroxysuccinimide ester 
(Pierce Chemical Co.) as described [33], mixed with Freund's adjuvant 
and injected to sheep. Polyclonal antibodies against each individual 
peptide were affinity purified from crude sera using BSA-conjugated 
peptide as previously described [34]. 
Microsomes from various rabbit tissues, crude rabbit skeletal mus- 
cle sarcolemma, nd purified DGC were prepared as previously de- 
scribed [3,35]. Proteins were resolved on 3-12% SDS-PAGE and elec- 
trotransferred to nitrocellulose membranes. Nitrocellulose membranes 
were blocked in Blotto (50 mM sodium phosphate, pH 7.4, 150 mM 
sodium chloride, 5°/,, non-fat dry milk) and subsequently incubated 
overnight with primary antibody. The primary antibodies used were 
affinity purified anti-y-sarcoglycan peptide from sheep, affinity purified 
anti-[3-sarcoglycan from rabbit [15] and affinity purified anti-dystro- 
phin, anti-~[3-dystroglycan, ti-syntrophins and anti-a-sarcoglycan 
from sheep [22]. Immunoblots were then washed with Blotto and 
incubated for 1 h with peroxidase-conjugated s condary antibody 
(Boerhinger-Mannhein) at a dilution of 1:1,000. After washing the 
nitrocellulose blots with Blotto, they were developed in 50 mM 
Tris-HC1, pH 7.5, 150 mM NaC1 using 4-chloro-l-naphthol as sub- 
strate or by ECL (Amersham). For immunofluorescence, 7 gm trans- 
verse cryosections were prepared from rabbit, mouse and human mus- 
cle or from LGMD2C patient muscle. Sections were treated with 
avidin/biotin blocking solutions (Vector), blocked with 5% BSA in 
PBS for 30 min, and then incubated for 90 min with primary anti- 
bodies described above. After extensive washing with PBS, sections 
were incubated with biotinylated secondary antibodies for 30 min, 
washed with PBS, and then incubated with FITC-conjugated strepta- 
vidin (Jackson immunoresearch laboratories) for 30 min. After wash- 
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Fig. 1. Characterization of 7-sarcoglycan peptide antibodies.(Left panel) Rabbit skeletal muscle total membranes (Mic), crude sarcolemmal 
membranes (CSM) and purified dystrophin glycoprotein complex (DGC) were resolved on SDS-PAGE and electrotransferred to nitrocellulose 
membrane. The nitrocellulose membranes were immunoreacted with affinity purified anti 7-sarcoglycan peptide antibodies and developed with 
4-chloro-l-naphthol as substrate. Molecular mass standards (103) are indicated on the left. (Right panel) Immunofluorescence of human, rabbit 
and mouse quadricep muscles tained with affinity purified anti y-sarcoglycan peptide antibodies. All photographs were taken at the same expo- 
sure and magnification. 
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ing with PBS, sections were mounted with FITC-guard (Testog) and 
observed under a Zeiss Axioplan fluorescence microscope. Photo- 
graphs were taken under identical conditions with the same exposure 
time. 
Monoclonal IgG IVD31 against ct-sarcoglycan [22], was purified 
with protein G Sepharose (Pharmacia) using standard procedures. 
10 mg of purified IgG were oxidized with NaIO4 and coupled to 
5 ml of Avidchrom hydrazide resin (Unisyn Technologies) using the 
manufacturer's standard procedure. The column was stored at 4°C in 
50 mM Tris pH 7.4, 500 mM NaCI and 0.01% NaNa. 
Rabbit skeletal muscle KC1 washed microsomes (1 g) were resus- 
pended in 50 ml of Buffer A (50 mM Tris-HC1 pH 7.4, 500 mM NaC1, 
1% SDS, 0.1 mM PMSF, 0.75 mM benzamidine, 2.5 I.tg/ml aprotinin, 
2.5 gg/ml leupeptin, and 0.5 gg/ml pepstatin A) and incubated at 
room temperature for 20 min. After incubation, solubilized micro- 
somes were centrifuged at room temperature for 30 min at 
100,000xg and the supernatant (SDS-extract) was decanted from 
the membrane pellet (SDS-pellet). The SDS-extract was supplemented 
with Triton X-100 to a final concentration of 5% and incubated over- 
night at 4°C with the anti-ct-sarcoglycan affinity column. The affinity 
column was extensively washed with buffer A containing 5% Triton 
X-100 and eluted with 20 ml of 50 mM glycine pH 2.5. The eluate was 
neutralized with 1 ml of 2 M Tris pH 8 and concentrated to 1 ml. 
SDS-pellet, SDS-extract, voids and concentrated luates were resolved 
by 3-12% gradient SDS-PAGE, electrotransferred to nitrocellulose 
membranes and subjected to Western blotting with DGC antibodies. 
Biopsies of deltoid, quadriceps or gastroenemius muscles from 9 pa- 
tients were studied either by immunofluorescence or immunoblotting. 
In 5 of these patients (3 Algerian and 2 Europeans) belonging to 
5 different family linkages to chromosome 13q12 were demonstrated. 
In the 4 other patients (1 Algerian, 2 Europeans and 1 Algerian and 
European) it was not possible to obtain significant results from link- 
age studies, but mutations on adhalin gene were excluded. Ages of 
onset of the clinical manifestations in the 9 patients were comprised 
between 3 and 8 years and the muscle biopsies were carried out be- 
tween the ages of 6 and 25 years. The clinical pathological picture of 
all patients correspond to that of SCARMD as reported by Ben 
Hamida et al. [21]. It resembled that of Duchenne or Becker muscular 
dystrophies with raised serum creatine kinase, particularly in early 
stages of the disease and a histological necrotic regenerating pattern 
without dystrophin deficiency. 
3.  Resu l ts  
To characterize the 35 kDa component of the DGC, pur- 
ified rabbit skeletal muscle DGC was separated by SDS- 
PAGE and transferred to PVDF membrane. The region of 
the membrane containing the 35 kDa protein was excised 
and the immobilized protein was digested with trypsin. Pep- 
tides were purified by reverse-phase HPLC and subjected to 
amino acid sequencing by Edman degradation. Eight different 
peptide sequences were obtained and during the process of 
preparing this manuscript for publication, Noguchi et al. 
[17] reported the primary structure of y-sarcoglycan. All the 
peptide sequences that we obtained were found in the reported 
amino acid sequence of y-sarcoglycan. Together, the peptide 
sequences contain 105 amino acids, which represent more 
than one third of the total protein sequence and contains 
292 amino acids. 
In order to obtain specific antibodies to y-sarcoglycan, sev- 
eral peptide sequences that we obtained by protein sequen- 
cing, were synthesized and conjugated to KLH before injec- 
tion into sheep. Polyclonal antibodies against each individual 
peptide were affinity purified with BSA-conjugated peptide. 
The affinity-purified antibodies were then tested on Western 
blot for reactivity to y-sarcoglycan. As shown in Fig. 1, an 
affinity purified polyclonal antibody raised against a peptide 
(VTGPEGALFEHS)  which corresponds to amino acids 167- 
178 of the reported y-sarcoglycan sequence specifically reacts 
on immunoblotting with a single protein band at 35 kDa in 
crude rabbit skeletal muscle microsomes, sarcolemmal mem- 
branes and purified DGC. In immunofluorescence studies, 
affinity-purified anti-peptide antibodies electively stained the 
sarcolemma of rabbit, mouse, and human skeletal muscle 
(Fig. 1) and colocalized with all other components of the 
DGC (data not shown). These data demonstrate the specifi- 
city of the y-sarcoglycan polyclonal antibodies. 
To establish the tissue-specific expression of y-sarcoglycan, 
immunoblot analysis was performed. Blots containing mem- 
brane preparations of various rabbit tissues were probed with 
the affinity purified anti-peptide antibodies (Fig. 2). y-Sarco- 
glycan was detected specifically in skeletal, cardiac and dia- 
phragm muscles. A protein band of approximately 65 kDa is 
also specifically detected in brain. Noguchi et al. [17] did not 
detect y-sarcoglycan mRNA in brain by Northern blot analy- 
sis. However, it is possible that similar to the case with ~-sar- 
coglycan, the level of brain y-sarcoglycan mRNA is low and 
prolonged exposure is required for detection of the messager 
in this tissue. Therefore, it is likely that the 65 kDa protein 
detected in brain with the specific y-sarcoglycan antibodies 
may correspond to a brain specific y-sarcoglycan isoform. 
However, we do not exclude the possibility that this protein 
contains the antibody epitope and is unrelated to y-sarcogly- 
can. 
In order to determine the status of y-sarcoglycan i  patients 
with LGMD2C,  linkage analysis was performed on several 
unrelated families with SCARMD.  Using polymorphic mar- 
kers, the genetic defect was linked to chromosome 13q12 in 
several families (data not shown). Skeletal muscle biopsy spe- 
cimens from these patients with LGMD2C were examined by 
immunofluorescence. Serial frozen sections were stained with 
antibodies to y-sarcoglycan or with antibodies to other com- 
ponents of the DGC. Fig. 3A shows the results of an immu- 
nofluorescence study from one patient. Dystrophin is present 
at comparable levels with control muscle; however, the im- 
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Fig. 2. Tissue distribution of y-sarcoglycan. Total membranes from 
various rabbit tissues were resolved by SDS-PAGE and electrotrans- 
ferred to nitrocellulose membrane. The nitrocellulose membrane was 
immunoreacted with affinity purified anti 7-sarcoglycan antibodies 
and developed with 4-chloro-l-naphthol as substrate. Molecular 
mass standards (10 z) are indicated on the left. 
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munostaining of 7-sarcoglycan is absent with a concomitant 
reduction of ~x- and [3-sarcoglycan (Fig. 3A). ~/[~-Dystrogly- 
can and syntrophin staining are comparable to control muscle 
(data not shown). Similar immunostaining results were ob- 
tained for all the chromosome 13q12 linked patients (data 
not shown), indicating that one characteristic of LGMD2C 
is a primary deficiency in y-sarcoglycan. To further character- 
ize the y-sarcoglycan defect in LGMD2 patient, total skeletal 
DYS 
CONTROL PATIENT 
a-SG 
p-SG 
7"SG 
\ 
B 
A 
g 7-sarcoglycan 
Fig. 3. Specific deficiency of y-sarcoglycan in LGMD2C. (A) lmmu- 
nofluorescence of human control (control) and LGMD2C patient 
(patient) deltoid muscles tained with affinity purified anti-dystro- 
phin (DYS), 0t-sarcoglycan (~x-SG), ~-sarcoglycan (~-SG) and y-sar- 
coglycan (y-SG) antibodies. All photographs were taken at the same 
exposure and magnification (× 160). (B) Total muscle xtracts from 
human control (control) and LGMD2 patients (patient) were re- 
solved on SDS-PAGE and electrotransferred to nitrocellulose mem- 
branes. The nitrocellulose membrane was immunoreacted with affi- 
nity purified anti 7-sarcoglycan tibodies and developed by ECL. 
Patient 1 and 4 are linked to chromosome 13q12 whereas no link- 
age data were obtain for patient 2 and 3. 
muscle extracts were subjected to immunoblot analysis with 
the specific affinity purified y-sarcoglycan antibodies. 7-Sarco- 
glycan was clearly detected in control muscle but we were 
unable to detect y-sarcoglycan i skeletal muscle from one 
chromosome 13 linked patient as well as in two patients with- 
out linkage data (Fig. 3B), suggesting that these two patients 
may be linked to chromosome 13q12. In another chromosome 
13 linked patient, y-sarcoglycan ppears to be greatly reduced. 
Taken together, our results demonstrate hat the genetic de- 
fect in LGMD2C leads to either a great reduction or a com- 
plete absence of 7-sarcoglycan i skeletal muscle. It also ap- 
pears that the absence of 7-sarcoglycan leads to a reduction of 
cx- and [~- sarcoglycan suggesting a close association between 
these three proteins in muscle sarcolemma. 
The close association of these sarcoglycan proteins has pre- 
viously been suggested by Yoshida et al. [36]. They have 
shown that n-octyl-13-D-glucoside isrupts the DGC into 
four groups of proteins: (i) ~- and [3-dystroglycan; (ii) dys- 
trophin; (iii) the syntrophins; and (iv) c~-, 13- and y-sarcogly- 
can. However, a direct demonstration f an association be- 
tween the sarcoglycan proteins has never been demonstrated 
in skeletal muscle sarcolemma. In order to determine whether 
or not the three sarcoglycan proteins are tightly associated in 
sarcolemma, crude rabbit skeletal muscle membranes were 
solubilized with SDS and applied over an affinity column 
consisting of c~-sarcoglycan monoclonal antibody coupled to 
Avidchrom hydrazide resin. After extensive washing, the anti- 
body affinity column was eluted with pH 2.5 glycine buffer. 
SDS solubilized membranes, column void and column eluate 
were analyzed by SDS-PAGE and immunoblotted using spe- 
cific antibodies to the DGC components. As shown in Fig. 4, 
all the DGC components except the syntrophins can be re- 
moved from the membrane with SDS. Western bot analysis of 
the antibody affinity column void and eluate reveal that dys- 
trophin and ~[3-dystroglycan are exclusively recovered in the 
void whereas cx-, [3- and 7-sarcoglycan are coeluted from the 
column (Fig. 4). Thus, these results clearly demonstrated that 
the sarcoglycan complex composed of ~x-, ~- and y-sarcogly- 
can exists as an unique entity at the sarcolemma. Further- 
more, the fact that SDS does not disrupt the sarcoglycan 
complex suggests that these three proteins are tightly asso- 
ciated. 
4. Discussion 
In conclusion, we confirmed here that SCARMD linked to 
chromosome 13q12 or LGMD2C is characterized by a specific 
absence or great reduction of y-sarcoglycan i  skeletal muscle. 
This characterization has been made possible by the produc- 
tion of specific and reliable anti-y-sarcoglycan antibody raised 
against a y-sarcoglycan peptide. Diagnosis of LGMD2C may 
now be possible by immunofluorescence or immunobloting 
analysis of muscle biopsies rather than linkage analysis, a pro- 
cedure which is not always possible due to inadequate family 
size. It is interesting to notice that in a previous tudy using 
antibodies raised against the 35 kDa protein band of the DGC, 
a reduction of staining at the sarcolemma of patients with 
LGMD2C was observed [22]. In contrast in this study using 
the y-sarcoglycan peptide antibody, all patients with 
LGMD2C tested displayed a complete absence of staining at 
the sarcolemma. These divergent results may suggest that the 
first antibody raised against he 35 kDa protein band of the 
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DGC recognized another 35 kDa protein in addition to y-sar- 
coglycan and this protein corresponds to an uncharacterized 
protein of the DGC. This could explain the residual staining at 
the sarcolemma of patients with LGMD2C using the antibo- 
dies raised against the 35 kDa protein band of the DGC [22]. 
Furthermore, we demonstrate the existence of a subcomplex 
within the DGC, composed of et-, ~- and y-sarcoglycan. In 
LGMD2C,  2D and 2E, the loss of one sarcoglycan protein 
leads to a reduction or absence of the two other members, 
indicating that mutations in one component affect the stability 
or targeting of the other components. Therefore, it appears 
that the disruption of the entire sarcoglycan complex causes 
LGMD2C,  -2D and -2E, in opposition to LGMD2A where 
mutations in calpain 3 gene cause the dystrophic phenotype 
[37]. The precise function of the sarcoglycan complex has yet 
to be determined. In Duchenne muscular dystrophy, the ab- 
sence of dystrophin causes a disruption of the DGC which 
leads to the loss of the functional ink between the extracel- 
lular matrix and the cytoskeleton and results in sarcolemma 
instability. It is likely that the sarcoglycan complex plays a 
similar role in maintaining the structural and functional in- 
tegrity of the sarcolemma. Furthermore, ~- and y-sarcoglycan 
seem to be also expressed in brain whereas c~-sarcoglycan is a 
muscle specific protein, suggesting that [3- and y-sarcoglycan 
may be part of another subcomplex in this tissue. It will be of 
interest o determine the structure and cellular localization of 
these two proteins in brain and to identify their associated 
proteins. 
a-sarcoglycan I~-sarcoglycan 
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